MediWound Ltd (MediWound) is a biotechnology niche specialty company that develops, manufactures and markets novel products that address unmet needs in severe burn and chronic wound management areas. The company’s commercial product, NexoBrid is topically applied novel biopharmaceutical product that removes eschar (dead or damaged tissue) in around four hours without harming the local healthy tissues. It is less invasive than surgery in removing eschar in patients with burn wounds.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MediWound’s research and development activities are focused at developing additional wound care products that have potential proprietary use in treating soft tissues and additional indications for its currently available product. In FY2022, the company spent US$9.4 million on R&D. which increased of 5.0%. As of December 31, 2022, the company had been granted 85 patents and 11 pending patent applications. NexoBrid is covered by 13 patents and 6 patents national phase applications.